Emmaus Life Sciences, Inc. (EMMA) — SEC-Verified Company Profile

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases. Its sole product, Endari (prescription grade L-glutamine oral powder), is FDA-approved to reduce acute complications of sickle cell disease in adults and pediatric patients aged five and older. Endari is also approved in UAE, Qatar, Kuwait, Bahrain, and Oman, and sold through distributors in the U.S. and MENA region.

Products

Name	Type	Description
Endari (prescription grade L-glutamine oral powder)	service	FDA-approved oral powder to reduce acute complications of sickle cell disease in adults and pediatric patients five years and older.

Partnerships

Partner	Type	Description
NeoImmuneTech, Inc. (NIT)	licensing	Exclusive license and distribution agreement granting NIT rights to market, sell, and distribute Endari and generic equivalents in the U.S. and Canada in exchange for upfront payment and royalties.
NeoImmuneTech, Inc. (NIT)	strategic	Exclusive Supply Agreement under which Emmaus agrees to supply exclusively to NIT all requirements for licensed products at cost plus a specified double-digit percentage margin.
Unnamed U.S. academic medical center	licensing	Exclusive 18-month option agreement to negotiate a worldwide exclusive license for patent rights related to an early clinical-stage metabolic therapy targeting pancreatic cancer.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/EMMA/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub